FULL-TEXT ARTICLE
Low Efficacy
of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4
and HIV Coinfection.
Macías J, López-Cortés LF, Téllez F, et
al
PLoS One.
2015 Dec 7;10(12):e0143492.
Paper
Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers (BTMs) in
HIV/HCV Co-Infected Patients.
Bedimo R, Kang M, Tebas P, et al
AIDS Res Hum Retroviruses.
2015 Oct 23.
Abstract
Impact of HIV infection on sustained virological response to treatment against
hepatitis C virus with pegylated interferon plus ribavirin.
Monje-Agudo P, Castro-Iglesias A, Rivero-Juárez A,
et al
Eur J Clin Microbiol Infect Dis.
2015 Jul
9
Abstract
FULL-TEXT
ARTICLE
Long-Term Consequences of Hepatitis C Viral Clearance on the CD4
(+) T Cell Lymphocyte Course in HIV/HCV Coinfected Patients.
Dazley J, Sison R, Slim J
AIDS
Res Treat. 2015;2015:687629.
Paper
The clinical effectiveness of pegylated interferon and ribavirin for the
treatment of chronic hepatitis C in HIV-infected patients in Brazil: a
multicentric study.
Ferreira PR, da Silva MH, Brandão-Melo CE, et al.
Braz J Infect Dis. 2014 Aug 30.
Abstract
OPERA: responses to peginterferon and ribavirin therapy in a
subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection
in Italy.
Bruno R, Cariti G, Nasta P,
et al
Liver Int. 2014 Jul 19.
Abstract
Sustained virological response in HIV/HCV Co-infected patients treated
with pegylated interferon/ribavirin can be predicted from the overall rate
of viral load decline over the first 4 weeks of therapy.
Rivero-Juarez A, Neukam K, Labarga P, et Al
J Infect. 2013 Nov 21.
Abstract
IFN/RBV Treatment for HCV is Associated with Development of
Hypophosphatemia in HIV/HCV Coinfected Patients.
Funk E, Shaffer A,
Shivakumar B, Sneller M,
et al
AIDS Res Hum Retroviruses.
2013 May 23.
Abstract
FULL-TEXT ARTICLE
Differences in HCV Viral Decline between Low and Standard-Dose
Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV
Genotype 3 Patients.
Rivero-Juárez A, Lopez-Cortes LF, Camacho A, et al
PLoS One.
2012;7(11):e48959.
Paper |
mpact of Peginterferon Alfa and Ribavirin Treatment on Lipid Profiles
and Insulin Resistance in HCV/HIV
Coinfected Persons: The AIDS Clinical Trials Group A5178 Study.
Butt AA, Umbleja T, Andersen JW
,lin
Infect Dis. 2012 May 4
Abstract
Randomized Trial Comparing Dose Reduction and Growth
Factor Supplementation for Management of Hematological Side Effects in
HIV/HCV Patients Receiving Pegylated-Interferon and Ribavirin.
Talal AH, Liu RC, Zeremski M,
et al
J Acquir Immune Defic Syndr.
2011 Aug 26.
Abstract
Peginterferon alfa and ribavirin for chronic hepatitis C in patients
eligible for shortened treatment, re-treatment or in HCV/HIV
co-infection: a systematic review and economic evaluation.
Hartwell D, Jones J, Baxter L,
Shepherd J.
Health Technol Assess. 2011 Apr;15(17):1-210.
Abstract
Twelve week post-treatment follow-up predicts sustained
virological response to pegylated interferon
and ribavirin therapy in
HIV/hepatitis C virus co-infected patients.
Rivero-Juárez A, Mira JA, Pérez-Camacho I, et al
J Antimicrob Chemother. 2011
Mar 17.
Abstract
Differences in liver fibrosis and response to pegylated interferon
plus ribavirin in
HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Maida I, Martin-Carbonero L, Sotgiu G, et al
J Viral Hepat.
2010 Jan 18
Abstract |
HIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated
Interferon
and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse
Events
Than Nonresponders Do.
Osinusi A, Rasimas JJ, Bishop R, et al
J Acquir Immune Defic Syndr.
2010 Jan 23
Abstract |
Alpha-interferon versus peg-interferon associated to ribavirin in the
treatment of genotype 1
hepatitis C virus and human immunodeficiency virus coinfected
patients]
Almeida PR,
Tovo CV, Rigo JO, et al
Arq Gastroenterol.
2009 Apr-Jun;46(2):132-7.
Abstract |
Efficacy of pegylated interferon plus ribavirin treatment in
HIV/hepatitis C virus co-infected patients
receiving abacavir plus lamivudine or tenofovir plus either lamivudine
or emtricitabine as nucleoside
analogue backbone.
Mira JA, López-Cortés LF, Barreiro P,
et al
Antimicrob Chemother. 2008 Oct 13
Abstract
|
Low response to pegylated interferon plus ribavirin in HIV-infected patients
with chronic hepatitis C treated
with abacavir.
Vispo E, Barreiro P, Pineda JA, et al
Antivir Ther. 2008;13(3):429-37
Abstract
The use of trough ribavirin concentration to predict sustained
virological response and
haematological toxicity in HIV/HCV-co-infected patients treated with
ribavirin and
pegylated interferon.
Marucco DA, de Requena DG, Bonora S, Tet al
J Antimicrob Chemother. 2008 Jan 31
Abstract
|
Peg
Inf alfa 2a Main
Main
New/Newsworthy
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
